3 Reasons Why GlaxoSmithKline plc Is More Than Just A Great Income Stock

Although it offers a great yield, there’s more to GlaxoSmithKline plc (LON: GSK) than just income.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With interest rates remaining at historic lows (and looking as though they could remain there for a while), stocks with relatively high yields have become increasingly popular. For instance, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) currently yields 5.2% and, despite allegations of bribery, has been a popular choice for investors seeking an income. However, there’s more to GlaxoSmithKline than just a high yield.

A Superb Pipeline

Although many of its pharmaceutical peers are struggling to come to terms with the impact of patent expiries on key drugs and the inevitable generic competition that follows, GlaxoSmithKline has been able to overcome such problems through having a strong and robust pipeline of new drugs. For instance, the company outlined at the start of 2013 six drugs that were in late-stage development and which it felt were key to the future profitability of the company. Five of the six drugs were approved during the course of the year, which is highly positive for the business and shows it has the potential to continue to deliver top-line growth in future.

gskIncreased Specialisation

GlaxoSmithKline has in recent years decided to specialise in pharmaceuticals and, specifically, in researching and developing new drugs. To this end, it has disposed of consumer goods interests (notably the sale of brands Ribena and Lucozade) so as to allocate more resources to the area where it feels it can maximise profitability for shareholders. This refocus could have a positive impact on the bottom-line over the medium to long-term.

Great Value

As mentioned, GlaxoSmithKline has been the subject of bribery investigations and they have caused share price weakness in recent months. Indeed, shares are down 3% during the course of the year, with the FTSE 100 down 2% year-to-date.

The positive aspect of this is that the stock now trades on a price to earnings (P/E) ratio of just 13.9. Although this is higher than the FTSE 100’s P/E of 13.3, the potential that GlaxoSmithKline offers through its attractive pipeline of new drugs, as well as increased specialisation in what is already a highly successful segment for the firm, means that it appears to be a price worth paying.

And if that isn’t enough, it’s a great income stock, too.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

Is Nvidia stock set for a massive crash?

Nvidia stock is up 3,500% in five years. So has AI fever sent it ridiculously high now, or are we…

Read more »

Investing Articles

Turning a £20k ISA into a stunning £38,023 a year passive income

Harvey Jones says investing regular sums in a Stocks and Shares ISA is a brilliant way of building up a…

Read more »

Growth Shares

Growth stock YouGov just fell 46%. Time to buy?

YouGov’s share price just fell from 820p to 440p after a poor trading update. Is now a good time to…

Read more »

Investing Articles

2 mouthwatering FTSE growth stocks I’d buy and hold for 10 years

Growth stocks purchased today could be the gateway to many years of capital growth and returns. Here are two picks…

Read more »

Investing Articles

Can the IAG share price really be as dirt cheap as it looks?

While most shares have recovered since the Covid days, the IAG share price is staying stuck to rock bottom. Surely…

Read more »

Investing Articles

BAE Systems shares are flying! Have I missed the boat?

Sumayya Mansoor looks into whether or not BAE Systems shares are still a good buy for her portfolio after the…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

1 heavyweight FTSE 100 share I’d buy as London retakes its crown

Some Footsie firms are extremely large, but that doesn't mean they couldn't get even bigger. Here's one such FTSE 100…

Read more »

Investing Articles

I’d buy 5,127 National Grid shares to generate £250 of monthly passive income

With a dividend yield of 6.5%, Muhammad Cheema takes a look at how National Grid shares can generate a healthy…

Read more »